Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
A Multicenter, Open-Label, Seamless Phase Ib/II Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Zeprumetostat (SHR2554) in Patients With Relapsed or Refractory NK/T-Cell Lymphoma
Rong Tao
107 participants
Apr 30, 2026
INTERVENTIONAL
Conditions
Summary
This is a multicenter, open-label, phase Ib/II study evaluating tislelizumab in combination with zeprumetostat (SHR2554) in patients with relapsed or refractory NK/T-cell lymphoma after at least one prior asparaginase-based chemotherapy-containing regimen, with or without radiotherapy. In phase Ib, two fixed dose levels of zeprumetostat in combination with tislelizumab will be evaluated to determine the recommended phase II dose (RP2D). In phase II, patients will be enrolled into 2 predefined cohorts according to prior exposure to PD-1 inhibitors to further evaluate efficacy and safety. The primary phase II endpoint is objective response rate at week 12 assessed by independent blinded imaging review according to Lugano 2014 criteria.
Eligibility
Inclusion Criteria11
- Age 18 years or older.
- Pathologically confirmed NK/T-cell lymphoma.
- Relapsed or refractory disease after at least 1 prior asparaginase-based chemotherapy-containing regimen, with or without radiotherapy.
- At least 1 measurable or evaluable lesion according to Lugano 2014 criteria.
- ECOG performance status 0 to 2.
- Life expectancy greater than 12 weeks.
- Adequate hematologic, hepatic, renal, coagulation, and cardiac function.
- Recovery from prior anti-cancer treatment-related toxicities to CTCAE grade 1 or baseline, except for specified stable irreversible toxicities allowed by the investigator.
- Negative pregnancy test for women of childbearing potential.
- Willingness to use effective contraception.
- Written informed consent.
Exclusion Criteria14
- Prior treatment with any EZH1/2 or EZH2 inhibitor.
- Allogeneic hematopoietic stem cell transplantation within 5 years before study treatment.
- Autologous hematopoietic stem cell transplantation within 3 months before study treatment.
- Requirement for high-dose systemic corticosteroids or other immunosuppressive therapy within 14 days before study treatment, except permitted local/inhaled or short-course use.
- Cytotoxic chemotherapy not discontinued within 14 days before study treatment.
- Systemic anti-cancer therapy or investigational therapy within 4 weeks before study treatment.
- Major surgery within 4 weeks or radiotherapy within 90 days before study treatment.
- Active infection, including active/latent tuberculosis, HIV infection, active hepatitis B or C with detectable viral nucleic acid, or other clinically significant active viral infection.
- Uncontrolled cardiovascular disease.
- Persistent unresolved toxicities greater than CTCAE grade 1 from prior therapy, except alopecia.
- Gastrointestinal disorders or prior intestinal surgery that may impair oral drug absorption.
- Pregnancy or breastfeeding.
- Psychiatric illness or inability to provide informed consent.
- Any other condition that, in the investigator's judgment, makes the patient unsuitable for the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Tislelizumab 200 mg administered intravenously on day 1 of each 21-day cycle.
Zeprumetostat (SHR2554), an oral EZH2 inhibitor, administered twice daily. In phase Ib, dose levels are 300 mg BID and 350 mg BID. In phase II, zeprumetostat is administered at the recommended phase II dose selected from phase Ib.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07502768